PMID- 18288936
OWN - NLM
STAT- MEDLINE
DCOM- 20080506
LR  - 20220331
IS  - 1567-2050 (Print)
IS  - 1567-2050 (Linking)
VI  - 5
IP  - 1
DP  - 2008 Feb
TI  - Memantine treatment in patients with mild to moderate Alzheimer's disease already 
      receiving a cholinesterase inhibitor: a randomized, double-blind, 
      placebo-controlled trial.
PG  - 83-9
AB  - OBJECTIVE: To evaluate the efficacy and safety of memantine in patients with mild 
      to moderate Alzheimer's disease (AD) receiving cholinesterase inhibitor (ChEI) 
      treatment. METHODS: Participants (N= 433) with probable AD, Mini-Mental State 
      Exam (MMSE) scores between 10-22 (inclusive), and concurrent stable use of ChEIs 
      (donepezil, rivastigmine, galantamine) were randomized to placebo or memantine 
      (20 mg once daily) for 24 weeks. Primary outcomes were changes from baseline on 
      the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and on 
      Clinician's Interview-Based Impression of Change Plus Caregiver Input 
      (CIBIC-Plus) score. Secondary measures comprised the 23-item Alzheimer Disease 
      Cooperative Study-Activities of Daily Living Scale (ADCS-ADL(23)), 
      Neuropsychiatric Inventory (NPI), and MMSE. RESULTS: At the end of the trial, 
      there were no statistically significant differences between the memantine- and 
      placebo group on primary and secondary outcome measures. The incidence of adverse 
      events (AEs) was similar between the two groups, with no AE occurring in more 
      than 5% of memantine-treated patients and at a rate twice that of the placebo 
      group. CONCLUSIONS: In this trial, memantine did not show an advantage over 
      placebo based on protocol-specified primary or secondary analyses in patients 
      with mild to moderate AD on stable ChEI regimens. There were no significant 
      differences in tolerability and safety between the memantine- and placebo groups.
FAU - Porsteinsson, Anton P
AU  - Porsteinsson AP
AD  - Alzheimer's Disease Care, Research and Education Program, University of 
      Rochester, School of Medicine and Dentistry, Rochester, NY 14620, USA. 
      Anton_Porsteinsson@urmc.rochester.edu
FAU - Grossberg, George T
AU  - Grossberg GT
FAU - Mintzer, Jacobo
AU  - Mintzer J
FAU - Olin, Jason T
AU  - Olin JT
CN  - Memantine MEM-MD-12 Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Curr Alzheimer Res
JT  - Current Alzheimer research
JID - 101208441
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - W8O17SJF3T (Memantine)
SB  - IM
MH  - Activities of Daily Living
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*drug therapy/psychology
MH  - Cholinesterase Inhibitors/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Excitatory Amino Acid Antagonists/*therapeutic use
MH  - Humans
MH  - Memantine/*therapeutic use
MH  - Mental Status Schedule
MH  - Middle Aged
MH  - Neuropsychological Tests
MH  - Prospective Studies
MH  - Receptors, N-Methyl-D-Aspartate/*antagonists & inhibitors
MH  - Severity of Illness Index
MH  - Treatment Outcome
FIR - Au, W
IR  - Au W
FIR - Baumel, B
IR  - Baumel B
FIR - Wilks, K
IR  - Wilks K
FIR - Blass, J
IR  - Blass J
FIR - Cooper, G
IR  - Cooper G
FIR - Eisner, L
IR  - Eisner L
FIR - Lossada, M
IR  - Lossada M
FIR - Forchetti, C
IR  - Forchetti C
FIR - Grossberg, G
IR  - Grossberg G
FIR - Grosz, D
IR  - Grosz D
FIR - Kirby, L
IR  - Kirby L
FIR - Lipton, A
IR  - Lipton A
FIR - Littlejohn, T 3rd
IR  - Littlejohn T 3rd
FIR - Losk, S
IR  - Losk S
FIR - Ott, B
IR  - Ott B
FIR - Pfeiffer, E
IR  - Pfeiffer E
FIR - Potkin, S
IR  - Potkin S
FIR - Sadowsky, C
IR  - Sadowsky C
FIR - Safirstein, B
IR  - Safirstein B
FIR - Seiden, D
IR  - Seiden D
FIR - Shua-Haim, J
IR  - Shua-Haim J
FIR - Stark, S
IR  - Stark S
FIR - Thein, S
IR  - Thein S
FIR - Tuchman, M
IR  - Tuchman M
FIR - van Dyck, C
IR  - van Dyck C
FIR - Booker, G
IR  - Booker G
FIR - Harris, B
IR  - Harris B
FIR - Margolin, D
IR  - Margolin D
FIR - Ferguson, J
IR  - Ferguson J
FIR - Moldauer, L
IR  - Moldauer L
FIR - Pomara, N
IR  - Pomara N
FIR - Dubovsky, S
IR  - Dubovsky S
FIR - Mintzer, J
IR  - Mintzer J
FIR - Wilks, K
IR  - Wilks K
FIR - Porsteinsson, A
IR  - Porsteinsson A
FIR - Tilker, H
IR  - Tilker H
FIR - Wallace, J
IR  - Wallace J
FIR - Heiser, J
IR  - Heiser J
FIR - Ferris, S
IR  - Ferris S
FIR - Bartel, D
IR  - Bartel D
FIR - Kobetz, S
IR  - Kobetz S
FIR - Doody, R
IR  - Doody R
EDAT- 2008/02/22 09:00
MHDA- 2008/05/07 09:00
CRDT- 2008/02/22 09:00
PHST- 2008/02/22 09:00 [pubmed]
PHST- 2008/05/07 09:00 [medline]
PHST- 2008/02/22 09:00 [entrez]
AID - 10.2174/156720508783884576 [doi]
PST - ppublish
SO  - Curr Alzheimer Res. 2008 Feb;5(1):83-9. doi: 10.2174/156720508783884576.